Bausch Health’s Slow Rebuild Faces New Scrutiny After Lombard Odier Cuts Its Stake Bausch Health’s valuation suggests potential, but the stake cut shows how far the company still has to go to earn back full investor confidence.
These stocks are moving in today's pre-market session Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics.
Wall Street's Top 10 Stock Calls This Week - Saturday, Feb. 15 What has Wall Street been buzzing about this week? Here is a look at the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Feb. 10-14, 2025.
Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst Silence Therapeutics' Phase 2 data shows zerlasiran achieves over 80% Lp(a) reduction in ASCVD patients but faces dosing frequency challenges.
The 3 Best Gene Editing Stocks to Buy in August 2024 These are the best gene-editing stocks to buy as the biotechs pursue precision therapies to cure rare diseases.
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks It takes a special set of circumstances for high-growth stocks to double in value in one year but analyst says these three can do it.
